Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Andrew, I take exception to the comments by pharaoh. Not everyone in the world is materialistic as he seems to believe.

I do have an opinion as to the value of Onko Sure. I also know quite a bit about marketing and the efforts needed to be successful. I just don't think I am wrong when I say that Onko Sure has an unsurmountable uphill battle to be successful. It cannot be used as a general screen and it will not be successful in India. Just like in the UK in 2001, they sold some but the sales soon went to zero.

The only hope for the product is monitoring, not just CRC but any cancer it detects. It has that capability. The question remains, will it be used. I just don't think it will. FDP apparently according to the literature, can vary as much as 15% from test to test for reasons other than cancer. It could even vary 15% daily, the literature does not give a timeframe for variablilty.

That is why they chose the greater than or less than 15% as the indicator of cancer progression/non-progression. That is a fine line to walk and obviously produces errors.

Future doc wanted to be sure I told you the previous trials had about 75% late stage and 25% earlier stage cancers. You or anyone else tell me why or how they picked patients to follow for the FDA trial? Is that a typical distribution of CRC patients or did they have to use a lot of later stage CRC patients to get the number of patients with progression they needed. If they did not select the patients by random selection, then the results are biased and not typical of the ordinary day to day treatment of CRC patients.

I do not know the average stage of CRC where it is diagnosed and treated. That is something you need to know. A greater number of progressions come from the treated later stage cancers.

Even though the new trials will probably show that Onko Sure is better in early stage, it is going to take a long time for other doctors and scientists to actually sort out what sort of monitoring tests or combination of tests would be best.

Radient just does not have much time left to be successful.